S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.21%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.21%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.21%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.21%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
NASDAQ:TCRR

TCR2 Therapeutics - TCRR Stock Forecast, Price & News

$1.33
+0.07 (+5.56%)
(As of 11/30/2022 05:19 PM ET)
Add
Compare
Today's Range
$1.25
$1.34
50-Day Range
$1.26
$2.09
52-Week Range
$1.23
$5.51
Volume
138,150 shs
Average Volume
429,185 shs
Market Capitalization
$51.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
724.0% Upside
$11.00 Price Target
Short Interest
Healthy
4.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.73mentions of TCR2 Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.10) to ($2.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

96th out of 1,043 stocks

Biological Products, Except Diagnostic Industry

12th out of 172 stocks

TCRR stock logo

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock News Headlines

TCR2 Therapeutics (NASDAQ:TCRR) PT Lowered to $13.00
TCR² Therapeutics: Betting On A Solid Reversal
TCR2 Therapeutics GAAP EPS of -$0.72 beats by $0.04
See More Headlines
Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Company Calendar

Last Earnings
11/10/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/28/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRR
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+727.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-99,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.14 per share

Miscellaneous

Free Float
28,989,000
Market Cap
$51.41 million
Optionable
Not Optionable
Beta
1.77

Key Executives

  • Dr. Garry E. Menzel M.B.A. (Age 58)
    Ph.D., Pres, CEO & Director
    Comp: $916.8k
  • Dr. Patrick A. Baeuerle Ph.D. (Age 64)
    Founder & Member of the Advisory Board
    Comp: $47.02k
  • Mr. Peter Olagunju (Age 44)
    Chief Technical Officer
    Comp: $307.42k
  • Dr. Alfonso Quintas Cardama M.D. (Age 51)
    Chief Medical Officer
    Comp: $668.6k
  • Mr. Richard Roomberg
    VP of Corp. Controller
  • Mr. Eric M. Sullivan CPA (Age 42)
    Chief Financial Officer
  • Carl Mauch
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Margaret Siegel J.D.
    Head of Legal & Corp. Sec.
  • Dr. Angela Justice Ph.D. (Age 48)
    Chief People Officer
  • Dr. Rosemary Harrison Ph.D. (Age 39)
    Chief Bus. & Strategy Officer













TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCRR shares.
View TCRR analyst ratings
or view top-rated stocks.

What is TCR2 Therapeutics' stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month price objectives for TCR2 Therapeutics' shares. Their TCRR share price forecasts range from $5.00 to $18.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 720.9% from the stock's current price.
View analysts price targets for TCRR
or view top-rated stocks among Wall Street analysts.

How have TCRR shares performed in 2022?

TCR2 Therapeutics' stock was trading at $4.66 at the beginning of 2022. Since then, TCRR stock has decreased by 71.2% and is now trading at $1.34.
View the best growth stocks for 2022 here
.

Are investors shorting TCR2 Therapeutics?

TCR2 Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 1,240,000 shares, a drop of 35.1% from the October 31st total of 1,910,000 shares. Based on an average daily trading volume, of 223,300 shares, the short-interest ratio is currently 5.6 days. Currently, 4.0% of the shares of the company are short sold.
View TCR2 Therapeutics' Short Interest
.

When is TCR2 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our TCRR earnings forecast
.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Tang Capital Management LLC (9.68%), Vanguard Group Inc. (3.71%), BlackRock Inc. (2.65%), Renaissance Technologies LLC (1.83%), Two Sigma Advisers LP (1.02%) and Dimensional Fund Advisors LP (0.85%). Insiders that own company stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends
.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $1.34.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $51.80 million. The company earns $-99,810,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

The company employs 137 workers across the globe.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 11/30/2022 by MarketBeat.com Staff